Triumvira Immunologics Announces Clearance of IND and CTA by U.S. FDA and Health Canada for Its First TAC T-cell Therapeutic Product Candidate, TAC01-CD19
Clinical trials of TAC01-CD19 expected to begin in third quarter 2019 AUSTIN, Texas & HAMILTON, Ontario & TORONTO–(BUSINESS WIRE)– Triumvira Immunologics, Inc. (Triumvira), a private, clinical-stage biopharmaceutical company developing a novel...Read More >>